Biblio

20 resultats trouvés
Filtres: Auteur is Bennouna, J.  [Clear All Filters]
1
Pudlarz T., Montravers F., Garcia-Larnicol M-L., Kempf E., Bennouna J., de la Fouchardiere C., Tougeron D., Borg C., Mazard T., Chibaudel B. et al..  2020.  {[18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC). ANNALS OF ONCOLOGY. 31:S1434.
A
Taieb J., Taly V., Vernerey D., Bourreau C., Bennouna J., Faroux R., Desrame J., Bouche O., Borg C., Egreteau J. et al..  2019.  Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. ANNALS OF ONCOLOGY. 30:867.
Taieb J., Taly V., Vernerey D., Bourreau C., Bennouna J., Faroux R., Desrame J., Bouche O., Borg C., Egreteau J. et al..  2019.  Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. ANNALS OF ONCOLOGY. 30:867.
B
Bennouna J., Hiret S., Borg C., Bertaut A., Bouche O., Deplanque G., Francois E., Conroy T., Ghiringhelli F., G. Guetz D et al..  2017.  Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI. ANNALS OF ONCOLOGY. 28
Bennouna J., Hiret S., Borg C., Bertaut A., Bouche O., Deplanque G., Francois E., Conroy T., Ghiringhelli F., G. Guetz D et al..  2017.  Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI. ANNALS OF ONCOLOGY. 28
Bennouna J., Falchero L., Schott R., Bonnetain F., Coudert M., B. Yahia BHadj, Chouaid C..  2017.  Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study. JOURNAL OF THORACIC ONCOLOGY. 12:S1808.
Chouaid C., Falchero L., Schott R., Bonnetain F., Taguieva-Pioger N., Bennouna J..  2017.  Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study. REVUE DES MALADIES RESPIRATOIRES. 34:36-43.
C
Adenis A., Bennouna J., Etienne P.L, Bogart E., Francois E., Galais M.P, Ben Abdelghani M., Michel P., Metges J.P, Dahan L. et al..  2019.  Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). EUROPEAN JOURNAL OF CANCER. 111:12-20.
F
Malka D., Metges J-P., Elias D., Bennouna J., Bonnetain F., Dourthe L-M., Ben Abdelghani M., Radji A., Laplaige P., F. Laurent P et al..  2016.  First-line (1-L) bevacizumab plus chemotherapy (Bev/CT) in colorectal cancer (CRC) patients with potentially resectable liver only (LM) or liver and lung metastases (LLM): KRAS mutation analysis of the non-interventional PICASSO study. ANNALS OF ONCOLOGY. 27
I
Metges J.-P, Bennouna J., Rivoire M., Elias D., Bonnetain F., Dourthe L., Ben Abdelghani M., Radji R., Laplaige P., F. Laurent P et al..  2016.  Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study ANNALS OF ONCOLOGY. 27:114.
Metges J.-P, Bennouna J., Rivoire M., Elias D., Bonnetain F., Dourthe L., Ben Abdelghani M., Radji R., Laplaige P., F. Laurent P et al..  2016.  Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study ANNALS OF ONCOLOGY. 27:114.
L
Girard N., S. Girodet G, Duruisseaux M., Avrillon V., Roch B., Otto J., Cadranel J., Coudurier M., Moro-Sibilot D., Egenod T. et al..  2020.  Lorlatinib for advanced ROS1+non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. ANNALS OF ONCOLOGY. 31:S865.
P
Aparicio T., Bennouna J., Le Malicot K., Boige V., Taieb J., Bouche O., Francois E., Phelip J-M., Borel C., Faroux R. et al..  2017.  Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial. ANNALS OF ONCOLOGY. 28
Pages F., Andre T., Taieb J., Vernerey D., Henriques J., Borg C., Marliot F., Ben Jannet R., Louvet C., Mineur L. et al..  2020.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study y. ANNALS OF ONCOLOGY. 31:921-929.
Pages F., Andre T., Taieb J., Vernerey D., Henriques J., Borg C., Marliot F., Ben Jannet R., Louvet C., Mineur L. et al..  2020.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study (vol 31, pg 921, 2020). ANNALS OF ONCOLOGY. 31:1276.
Girard N., Greillier L., Zalcman G., Cadranel J., Moro-Sibilot D., Mazieres J., Audigier-Valette C., Bennouna J., Besse B., Cortot A. et al..  2020.  Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. RESPIRATORY MEDICINE AND RESEARCH. 78:100769.
T
Bennouna J., Etienne P.-L, Bogart E., Galais M.-P, Benabdelghani M., Francois E., Michel P., Dahan L., Metges J.-P, Ghiringhelli F. et al..  2016.  The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results. ANNALS OF ONCOLOGY. 27:141.
Bennouna J., Etienne P.-L, Bogart E., Galais M.-P, Benabdelghani M., Francois E., Michel P., Dahan L., Metges J.-P, Ghiringhelli F. et al..  2016.  The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results. ANNALS OF ONCOLOGY. 27:141.
Taieb J., Bonnetain F., Mineur L., Bennouna J., Desrame J., Faroux R., Fratte S., Dauba J., Vernerey D., Louvet C. et al..  2017.  Three versus six months' adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. ANNALS OF ONCOLOGY. 28
Basile D., Broudin C., Emile J-F., Falcoz A., Toullec C., Bennouna J., Louvet C., Desrame J., Fratte S., Andre T. et al..  2021.  Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy. ANNALS OF ONCOLOGY. 32:S533.